Company disclaimer

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck’s ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Lundbeck undertakes no duty to update forward-looking statements.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.
Q1 highlights

Sales development

• Revenue increased 33% excluding Lexapro US
• Continuous operations up 13%
• New Products* increased by 36%

R&D

• Selincro launched in selected EU markets
• Abilify Maintena launched in the US
• Partnership agreement with Otsuka for Lu AE58054

Financial performance

• Financial results for Q1 2013 in line with full year expectations
• 2013 outlook suggests revenue of DKK 14.4-15bn and EBIT of DKK 1.9-2.4bn

*New Products: Xenazine, Sabril, Sycrest, Lexapro (Japan), Onfi and Treanda
Continued robust momentum in new markets

**USA**
- Sales growth of 17% y/y in the quarter, excluding Lexapro
- Onfi generated DKK 96 million in the quarter, a growth of 94%

**Japan**
- Sales increased by 132% y/y in the first quarter in local currency
- Lexapro has a market share of 8.4%

**Europe**
- Sales increased 3% y/y in the quarter
- Azilect sales reached DKK 320 million with a growth of 24%

**Other**
- International Markets grew 17% in the first quarter
- China continues its solid performance growing 83% y/y in the quarter
Strong growth in New Products to be fueled by further launches

Revenue from New Products increased 36% y/y in the first quarter of 2013

All new products contribute to the growth in the quarter

New Products constitute 16% of total revenue in the quarter (excl. non-recurring items)

Three new products expected to be launched in 2013

- Abilify Maintena
- Selincro
- Brintellix - filed

*New Products include all current and potential products launched in the 2008-2015 period
Abilify Maintena launched in the US

- leverages on the extensive clinical experience with oral Abilify
- is set to expand the long-acting market in schizophrenia
- is expected to reach peak sales of DKK 2-2.5 billion (in total for Lundbeck)

- The global depot market amounts to USD 2.4 billion
  - CAGR of 21% from 2007-2011

Relapse has a significant negative impact on the patients with schizophrenia

Relapse is substantially driven by poor adherence

Adherence is primarily influenced by the patients’ poor insight and acceptance of the efficacy / side effect balance

Abilify Maintena can help physicians address those challenges and protect their patients from the natural course of the disease
Selincro launched in first European markets

- Selincro is the first and only product targeting alcohol reduction
- Strong interest in the concept from many stakeholders
- Selincro launched in Finland, Norway, Poland and Baltic countries
- Selincro is expected to significantly increase the treatment ratio from currently ~4%
- Peak sales DKK 2-2.5 billion

The Selincro Patient
- Alcohol dependent
- High risk drinking level
- No physical withdrawal symptoms/ no need for immediate detoxification
Lundbeck invests to grow – a solid late-stage development portfolio

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Registration app</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOOD DISORDERS</td>
<td>Tedatixetine*</td>
<td></td>
<td>Brintellix (Vortioxetine)</td>
</tr>
<tr>
<td></td>
<td>(Lu AA24530)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSYCHOSIS</td>
<td></td>
<td></td>
<td>Abilify Maintena (EU)</td>
</tr>
<tr>
<td>ALCOHOL DEPENDENCE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEPRESSION/SCHIZOPHRENIA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brexiprazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(OPC-34712)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALZHEIMER’S DISEASE</td>
<td>Lu AE58054</td>
<td>Lu AE58054</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPILEPSY</td>
<td></td>
<td></td>
<td>IV carbamazepine</td>
</tr>
<tr>
<td>OTHER</td>
<td></td>
<td></td>
<td>Desmoteplase (stroke)</td>
</tr>
</tbody>
</table>

*No active clinical programme ongoing
First data from “high-dose” program on Brintellix presented at EPA in March

- is a uniquely designed multimodal antidepressant that may provide unique clinical benefits
- is significantly better versus agomelatine in patients who switched antidepressant treatment after an inadequate response to SSRI/SNRi treatment
- showed consistent results over all endpoints
- ~10 posters to be presented at APA on 18-22 May 2013
Lundbeck and Otsuka expand alliance with Lu AE58054

- Co-development and co-commercialization agreement with Otsuka on Lu AE58054

- Lundbeck receives USD 150 million from Otsuka upon signing of agreement

- Clinical phase III program in Alzheimer’s is expected to be initiated in H2 2013
  - Three trials of more than 2,500 patients
  - Add-on to donepezil
  - Several active dose of Lu AE58054

- Clinical phase II study results planned to be presented at AAIC in Boston on 13-18 July 2013
Last quarter in the “shadow” of Lexapro US

Revenue increased by 13% to DKK 3,827 million, excl. Lexapro (US) and “one offs”

Cipralex revenue increased by 4% driven by France, Germany, Japan and Canada

Onfi continues to show solid growth by increasing revenue of 94% compared to Q1 2012

Azilect increased by 30% driven by the South European countries and the UK

*Other includes Other pharmaceuticals, Other revenue, Milestones and gains from divestiture
## Solid financial performance in the first quarter of 2013

<table>
<thead>
<tr>
<th>DKKm</th>
<th>Q1 2013</th>
<th>Q1 2012</th>
<th>Index</th>
<th>FY 2012</th>
<th>FY 2011</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4,576</td>
<td>3,778</td>
<td>121</td>
<td>14,802</td>
<td>16,007</td>
<td>92</td>
</tr>
<tr>
<td>- Continuous operations*</td>
<td>3,827</td>
<td>3,387</td>
<td>113</td>
<td>13,511</td>
<td>12,768</td>
<td>106</td>
</tr>
<tr>
<td><strong>R&amp;D costs</strong></td>
<td>660</td>
<td>680</td>
<td>97</td>
<td>2,919</td>
<td>3,319</td>
<td>88</td>
</tr>
<tr>
<td>- R&amp;D%</td>
<td>14%</td>
<td>18%</td>
<td></td>
<td>20%</td>
<td>21%</td>
<td></td>
</tr>
<tr>
<td><strong>EBIT</strong></td>
<td>1,526</td>
<td>882</td>
<td>173</td>
<td>1,726</td>
<td>3,395</td>
<td>51</td>
</tr>
<tr>
<td>- margin</td>
<td>33%</td>
<td>23%</td>
<td></td>
<td>12%</td>
<td>21%</td>
<td></td>
</tr>
<tr>
<td><strong>EPS</strong></td>
<td>5.44</td>
<td>3.16</td>
<td>172</td>
<td>5.94</td>
<td>11.64</td>
<td>51</td>
</tr>
<tr>
<td><strong>Cash flows from operations</strong></td>
<td>627</td>
<td>278</td>
<td>225</td>
<td>2,112</td>
<td>3,624</td>
<td>58</td>
</tr>
<tr>
<td><strong>Interest bearing net cash</strong></td>
<td>2,033</td>
<td>2,077</td>
<td>98</td>
<td>1,893</td>
<td>2,023</td>
<td>94</td>
</tr>
</tbody>
</table>

*Continuous operations = revenue excl. milestones, gains from divestment of US portfolio of non-core products, former revenue from US portfolio of non-core products and Lexapro US.
Financial guidance for 2013 maintained

<table>
<thead>
<tr>
<th>DKK</th>
<th>Reported 2012</th>
<th>Guidance 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>14,802m</td>
<td>14.4-15bn</td>
</tr>
<tr>
<td>EBIT</td>
<td>1,726m</td>
<td>1.9-2.4bn</td>
</tr>
</tbody>
</table>

- Continued elevated SG&A and R&D ratios
- USD 30 million in milestones related to Brintellix included
- USD 100 million gain related to divestiture of US products included
- USD 50 million upfront payment related to extension of partnership agreement with Otsuka for Lu AE58054 included
- Free cash flow expected to be impacted by milestone payments of up to USD 300 million to Otsuka
Expected main events in 2013

**H1 2013**
- Approval of Abilify Maintena the US
- Final approval of Selincro by the EU Commission
- Presentation of Brintellix data at APA 2013 on 18-22 May, San Francisco

**H2 2013**
- Presentation of Lu AE58054 data at AAIC 2013 in July in Boston
- Start of pivotal programme on Lu AE58054 in Alzheimer’s
- Approval of Brintellix in Europe (CHMP recommendation) and North America
- Headline conclusions on brexpiprazole phase III studies
- Headline conclusions on desmoteplase phase III (DIAS-3) study (end-year)
- Recommendation of Abilify Maintena from CHMP in Europe
Thank you...